EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Finite‐Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia—A Pilot Study

Li Ye, Mixue Xie, Gaixiang Xu iD, Chen Mei, Chao Hu, Xinping Zhou iD, Yanling Ren, Liya Ma, Chunmei Yang, Jiejing Qian, Jie Jin iD, Hongyan Tong iD

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 19.05.2026. Verfasst von Li Ye und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Azacitidine. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Natural Science Foundation of China grants, The Key R&D Program of Zhejiang, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Continuous venetoclax‐azacitidine (VA) therapy is currently the major intervention for elderly or unfit acute myeloid leukemia (AML) patients. However, moderate chemotherapy with finite‐duration VA could achieve comparable or superior efficacy to infinite‐duration VA. Additionally, umbilical cord blood (UCB) transfusion improves clinical safety for elderly patients. Therefore, this single‐center study presents an improved approach: A finite‐duration VA and decitabine priming with intermediate‐dose cytarabine followed by UCB infusion.

Methods

We included elderly AML patients who underwent the treatment between March 2021 and May 2024. Induction and maintenance regimens were VA. Our consolidation therapy involved intravenous decitabine (20 mg/m 2 d1–3), intermediate‐dose cytarabine (1.0 g/m 2 q12h d4–5), with subsequent UCB infusion (1.5% ± 25% × 10 7 /kg) d7. Our endpoints included duration of response (DOR), overall survival (OS), and safety.

Results

We analyzed 16 patients with a median follow‐up of 53.6 months (95% CI: 36.2–71.0 months), and 7 out of 16 participants were at adverse risk. The median VA cycle number prior to disease relapse was 5 (IQR: 4–6). The median DOR was 17.4 months (95% CI: 7.3–27.5 months), with a 1‐year DOR rate of 68.8% and a 2‐year DOR rate of 35.2%. The median OS was 24.9 months (95% CI: 9.8–40.1 months), with a 1‐ and 2‐year OS rate of 100% and 55.6%. Specifically, among the 8 patients with IDH1/2 mutations, 4 experienced sustained remission, with 1‐year OS of 100%. Hematological and non‐hematological toxicities remained manageable during the consolidation phase.

Conclusions

We demonstrated prolonged survival, particularly in patients with IDH mutations, using the modified intervention. This approach holds significant value for elderly patients with untreated AML who are unfit for standard treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesBridged Bicyclo Compounds, HeterocyclicAzacitidineAntineoplastic Combined Chemotherapy ProtocolsFetal BloodCord Blood Stem Cell TransplantationHumansPilot ProjectsFemaleAgedMaleFrail ElderlyAged, 80 and overTreatment OutcomeIsocitrate DehydrogenaseDecitabine

Stichwörter der Autor:innen

AzacitidineVenetoclaxacute myeloid leukemiaumbilical cord blood

Substanzen

SulfonamidesvenetoclaxBridged Bicyclo Compounds, HeterocyclicAzacitidineIsocitrate DehydrogenaseIDH2 protein, humanIDH1 protein, humanDecitabine

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Zhejiang, Hangzhou, People's Republic of China.
  • Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, People's Republic of China.
  • Zhejiang University Cancer Center, Hangzhou, People's Republic of China.

ORCID-Profile: Gaixiang Xu, Xinping Zhou, Jie Jin, Hongyan Tong

Förderung

  • The National Natural Science Foundation of China grants
  • The Key R&D Program of Zhejiang, China

Zitieren

APA

Ye, L., Xie, M., Xu, G., Mei, C., Hu, C., Zhou, X., Ren, Y., Ma, L., Yang, C., Qian, J., Jin, J., & Tong, H. (2026). Finite‐Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia—A Pilot Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71943

Vancouver

Ye L, Xie M, Xu G, Mei C, Hu C, Zhou X, et al. Finite‐Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia—A Pilot Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71943

BibTeX
@article{Ye2026,
  author = {Ye, Li and Xie, Mixue and Xu, Gaixiang and Mei, Chen and Hu, Chao and Zhou, Xinping and Ren, Yanling and Ma, Liya and Yang, Chunmei and Qian, Jiejing and Jin, Jie and Tong, Hongyan},
  title = {Finite‐Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia—A Pilot Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71943}
}
Kostenlos starten →